Spyre Therapeutics (SYRE) Other financing activities (2016 - 2023)

Spyre Therapeutics (SYRE) has 7 years of Other financing activities data on file, last reported at $1.8 million in Q2 2023.

• For the quarter ending Q2 2023, Other financing activities fell 12.0% year-over-year to $1.8 million; the trailing twelve-month figure through Jun 2023 stood at $6.5 million (down 22.14% YoY), and the FY2024 full-year result was $1000.0, up 106.25% from the prior year.
• Other financing activities for Q2 2023 stood at $1.8 million, up from $1.7 million in the prior quarter.
• Across five years, Other financing activities topped out at $2.1 million in Q3 2021 and bottomed at $1.1 million in Q1 2019.
• The 5-year median for Other financing activities is $1.7 million (2020), against an average of $1.7 million.
• The widest annual swing landed in 2020, when Other financing activities surged 36.15%; it then sank 31.85% in 2022.
• A 5-year view of Other financing activities shows it stood at $1.2 million in 2019, then jumped by 36.15% to $1.6 million in 2020, then increased by 29.9% to $2.1 million in 2021, then tumbled by 31.85% to $1.4 million in 2022, then grew by 24.39% to $1.8 million in 2023.
• The last three Other financing activities figures came in at $1.8 million (Q2 2023), $1.7 million (Q1 2023), and $1.4 million (Q4 2022), per Business Quant data.

Peer Comparison